Cullen Investment Group LTD. Increases Position in Pfizer Inc. (NYSE:PFE)

Cullen Investment Group LTD. increased its stake in Pfizer Inc. (NYSE:PFE) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,677 shares of the biopharmaceutical company’s stock after purchasing an additional 377 shares during the quarter. Cullen Investment Group LTD.’s holdings in Pfizer were worth $1,235,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC purchased a new position in Pfizer during the 3rd quarter valued at about $252,000. Quent Capital LLC increased its holdings in Pfizer by 15.0% during the 3rd quarter. Quent Capital LLC now owns 15,252 shares of the biopharmaceutical company’s stock valued at $442,000 after acquiring an additional 1,987 shares in the last quarter. Inspirion Wealth Advisors LLC increased its holdings in Pfizer by 0.8% during the 3rd quarter. Inspirion Wealth Advisors LLC now owns 52,377 shares of the biopharmaceutical company’s stock valued at $1,516,000 after acquiring an additional 420 shares in the last quarter. Mirador Capital Partners LP increased its holdings in Pfizer by 253.3% during the 3rd quarter. Mirador Capital Partners LP now owns 34,416 shares of the biopharmaceutical company’s stock valued at $996,000 after acquiring an additional 24,674 shares in the last quarter. Finally, Allied Investment Advisors LLC increased its holdings in Pfizer by 3.7% during the 3rd quarter. Allied Investment Advisors LLC now owns 259,203 shares of the biopharmaceutical company’s stock valued at $7,501,000 after acquiring an additional 9,223 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.8 %

PFE stock traded up $0.24 during midday trading on Friday, reaching $28.58. 28,786,884 shares of the company’s stock traded hands, compared to its average volume of 37,384,395. The company has a market capitalization of $161.95 billion, a P/E ratio of -476.33, a PEG ratio of 1.25 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The business has a 50-day moving average price of $29.17 and a two-hundred day moving average price of $28.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the company posted $0.67 earnings per share. Pfizer’s revenue was up 2.1% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Thursday. StockNews.com downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.